Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580267 | 0.85 | OPRM1 (0.50) | MEN1KMT2AATMOPRM1OPRD1 | |
| SCHEMBL579469 | 0.80 | OPRM1 (0.67) | MEN1KMT2AATMOPRM1OPRD1 | |
| SCHEMBL579606 | 0.79 | OPRM1 (0.65) | MEN1KMT2AATMOPRM1OPRD1 | |
| SCHEMBL580191 | 0.78 | GAA (0.58) | LMNAMEN1KMT2AATMOPRM1 | |
| SCHEMBL579444 | 0.77 | OPRM1 (0.60) | MEN1KMT2AATMOPRM1OPRD1 | |
| SCHEMBL579511 | 0.77 | OPRM1 (0.61) | LMNAMEN1KMT2AATMOPRM1 | |
| SCHEMBL580275 | 0.77 | NPC1 (0.56) | LMNAMEN1KMT2AATMOPRM1 | |
| SCHEMBL7706003 | 0.77 | LMNA (0.59) | LMNAMEN1KMT2AATMGAA | |
| SCHEMBL579839 | 0.76 | NPC1 (0.61) | LMNAMEN1KMT2AATMOPRM1 | |
| SCHEMBL580225 | 0.76 | SMN1; SMN2 (0.71) | LMNAMEN1KMT2AATMOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | claimed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | LMNA 3778/4885MEN1 4770/4885KMT2A 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.